Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity

Autor: Schoonheim, MM, Jonkman, LE, Eijlers, AJC, Meijer, KA, Killestein, J, Geurts, JJG
Přispěvatelé: Anatomy and neurosciences, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neuroinfection & -inflammation, AII - Inflammatory diseases, Neurology, Amsterdam Neuroscience - Neurodegeneration
Jazyk: angličtina
Rok vydání: 2019
Zdroj: 5th Congress of the European Academy of Neurology
Schoonheim, M M, Jonkman, L E, Eijlers, A J, Meijer, K A, Killestein, J & Geurts, J J 2019, ' Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity ', European Journal of Neurology, vol. 26, pp. 858-858 .
European Journal of Neurology, 26, 858-858. Wiley-Blackwell
Schoonheim, MM, Jonkman, LE, Eijlers, AJC, Meijer, KA, Killestein, J & Geurts, JJG 2019, ' Long-term natalizumab treatment is associated with a reduction in lesional white matter levels of myo-inostiol, a biomarker of gliotic activity ', 5th Congress of the European Academy of Neurology, Oslo, Norway, 29/06/2019-02/07/2019 .
ISSN: 1351-5101
Databáze: OpenAIRE
Externí odkaz: